DailyDoctor Archive Specialties Get app
Back to the 2 November 2026 edition

Research · 03 of 05

Empiric versus test-guided stone prevention gave similar urine risk at eight weeks

Where 24-hour urine testing is impractical, consider empiric prevention for recurrent calcium stones; this small trial found similar urine risk profiles.

Design
Single-centre randomised trial
Population
56 adults with recurrent idiopathic calcium stones
Primary outcome
Urinary supersaturation of calcium oxalate and calcium phosphate at 8 weeks
Effect
Calcium oxalate 4.7 vs 5.0 (P = 0.81); calcium phosphate 1.3 vs 1.4 (P = 0.58)

The single-centre URINE trial randomised 56 adults with recurrent idiopathic calcium stones to empiric prevention, with diet and fluid advice plus indapamide and potassium citrate for everyone, or to selective therapy tailored by 24-hour urine testing. It was published in June 2026.

At eight weeks, calcium oxalate supersaturation (4.7 vs 5.0) and calcium phosphate supersaturation (1.3 vs 1.4) did not differ, nor did urine volume, pH or excretion of calcium, oxalate, citrate or uric acid.

This challenges the assumption that 24-hour urine testing is needed before starting prevention in typical recurrent calcium stone formers. Where testing is costly or hard to collect, as it often is in India, an empiric approach may be reasonable.

The trial was small and short and measured urine chemistry, not stone recurrence, so it cannot show that the strategies prevent stones equally.

  • For recurrent calcium stones, empiric prevention gave similar urine chemistry to tailored therapy.
  • Consider empiric thiazide-type diuretic and citrate where 24-hour testing is impractical.
  • Keep 24-hour testing for unusual, frequent or childhood stones.
  • Monitor potassium and sodium on indapamide.

Why it matters

Testing before treating may add cost and delay without changing the urine.

Don't overread it

A small, eight-week trial of urine chemistry; it does not show equal stone recurrence.

The statistics, in plain English

No significant difference in a trial of 56 people means large differences are unlikely, but moderate ones could be missed. Supersaturation is a surrogate, not stone recurrence.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

prostatecancerbphstones

Tomorrow morning, before your first patient

One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app